Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Injectable Drugs for Type-2 Diabetes Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.
The primary factor for the growth of the market can be attributed to the increase in prevalence of type 2 diabetes globally. According to NCBI (National Center for Biotechnology Information), number of people affected by diabetes mellitus is expected to reach to a figure of more than 600 million. Additionally, type 2 diabetes mellitus account for nearly 90% of all diabetes cases. Owing to this rise in diabetic patients, the market for injectable drugs for type 2 diabetes is anticipated to grow significantly.
Injectable Drugs for Type-2 Diabetes Sector: Growth Drivers and Challenges
Growth Driver
Growing Diabetes Vulnerable Population to Drive Market
With increasing life expectancy and birth rate declining, median age of the world population is expected to rise. Old age people are generally more vulnerable towards diabetes, thereby the number of people with type 2 diabetes are expected to rise and hence provide an opportunity of the injectable drugs for type 2 diabetes market to grow.
Increasing Prevalence of Type 2 Diabetes to Boost Market Growth for Injectable Drugs
Type 2 diabetes is progressive in nature and its prevalence is increasing leading to the need of suitable treatment to fulfil the unmet needs of the body of patient. Injectable drugs serve as an option to fulfil those needs and it will drive the market growth in the forecast period.
Increasing Awareness About Type 2 Diabetes to Drive Market Growth
Organizations such as the International Diabetes Federation (IDF) conduct various community-level and global-level programs that focus on educating people and enhancing their knowledge about diabetes and its management. Globally, the World Diabetes Day is celebrated on November 14 by over 200 member associations of the IDF. Such programs will make people more aware about diabetes and will provide them knowledge to manage it in a better way using various kind of drugs available in the injectable drugs for type-2 diabetes market.
Restraints
Stringent Regulation Environment to Hamper Market Growth
In an effort to protect public from harmful drug effects, governments make rule and regulations stringent. Usually government regulations make product development more expensive. Such environment can create a hindrance in the market growth in that region.
Time Consuming Approval Process of Drugs to Restrain Market Growth
From the time of research and development to the official launch of drugs, it takes a very long time. Even after development and successful trials, approval from regulatory authority takes a lot of time and a lot of entrepreneurs and big players do not invest in drug manufacturing due to this reason. Over the forecast period this may hamper the growth of injectable drug for type 2 diabetes market.
Injectable Drugs for Type-2 Diabetes Segmentation
The injectable drugs for type-2 diabetes market is further segmented by drug type, drug application, distribution channel and region. The drug type segment is further divided into insulin, exenatide, liragultide and pramlintide. Segments other than insulin are relatively new to the market and they are expected to show moderate growth on the back of their rising awareness. In terms of application, these drugs are most commonly used for glycemic control owing to the requirement of sugar control in blood of the diabetes patients. Moreover, according to NCBI are more vulnerable towards type 2 diabetes and with the rise in old age population globally the need for cardiovascular safety rises as well. Additionally, with the increasing popularity of online pharmacies the supply chain in the field of drug delivery is expected to improve tremendously. On the back of these factors the global injectable drug for type 2 diabetes market is expected to grow notably over the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Drug Effect |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportInjectable Drugs for Type-2 Diabetes Industry - Regional Synopsis
North America industry is estimated to hold largest revenue share by 2037, backed by increasing prevalence of type 2 diabetes and obesity in the region.
Currently, North America region holds the maximum market share on the back of increasing prevalence of type 2 diabetes and obesity in the region along with the presence of world’s leading contributor, USA, in this field. Asian countries are expected to show significant growth owing to the initiatives taken by local government and health organizations to spread awareness about diabetes and its management using drugs and devices.
Companies Dominating the Injectable Drugs for Type-2 Diabetes Landscape
- AstraZeneca Plc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline Plc.
- Merck & Co., Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Novo Nordisk A/S
- Sanofi
- Eli Lilly and Company
In the News
- May 6, 2020 - Pharmaceutical giant AstraZeneca’s diabetes drug Farxiga has become the first in its class to win U.S. approval as a treatment for heart failure, opening up a major new market opportunity outside of the medicine’s established field.
- May 2020 - Danish drug maker Novo Nordisk stated that as per their research one of its marketed diabetes medication semaglutide, seems to work in another widespread disease, a liver condition known as NASH.
Author Credits: Radhika Pawar
- Report ID: 2557
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
